Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Finished Drug Prices
NA
1. 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2s)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one
2. Amg 510
3. Amg-510
4. Amg510
5. Lumakras
1. Amg-510
2. Amg510
3. 2296729-00-3
4. Lumakras
5. Amg-510 Racemate
6. Amg 510
7. 2252403-56-6
8. Kras G12c Inhibitor 9
9. Sotorasib [inn]
10. Sotorasib [usan]
11. Kras Mutant-targeting Amg 510
12. 4-((s)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1h)-one
13. 2b2vm6uc8g
14. Chembl4535757
15. 2296729-00-3 (racemate)
16. 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2s)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one
17. (1m)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2s)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1h)-one
18. (1s)-4-((s)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1h)-one
19. 2296729-66-1
20. 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2s)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one
21. Pyrido(2,3-d)pyrimidin-2(1h)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2s)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-
22. Sotorasibum
23. Lumykras
24. Pyrido(2,3-d)pyrimidin-2(1h)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2s)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-, (1r)-
25. Pyrido[2,3-d]pyrimidin-2(1h)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2s)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]-, (1r)-
26. Amg510 Racemate
27. Amg 510 Racemate
28. Amg-510(racemate)
29. Sotorasib [jan]
30. Sotorasib Racemate
31. Unii-2b2vm6uc8g
32. Sotorasib [who-dd]
33. Sotorasib [orange Book]
34. Schembl20560375
35. Gtpl10678
36. Chebi:178199
37. Amg 510 Pound>>amg-510
38. Dtxsid001099260
39. Glxc-25372
40. Amy16918
41. Bcp30452
42. Bcp33368
43. Ex-a3538
44. Bdbm50514402
45. Nsc818433
46. S8830
47. Who 11370
48. Akos037649138
49. Db15569
50. Nsc-818433
51. Ac-35168
52. Ba172505
53. Ba172506
54. Bs-16684
55. Hy-114277
56. Cs-0081316
57. Compound (r)-38 [pmid: 31820981]
58. D70074
59. D77975
60. A930071
61. A934531
62. Amg510 ; Amg 510; Amg-510; Amg510
63. (1r)-4-((s)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1h)-one
64. (1ra)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-4-((2s)-2-methyl-4-(1-oxoprop-2-en-1-yl)piperazin-1-yl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)pyrido(2,3-d)pyrimidin-2(1h)-one
65. 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1m)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2s)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1h)-one
66. 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(2-propanyl)-3-pyridinyl]-4-[(2s)-2-methyl-4-(2-propenoyl)-1-piperazinyl]pyrido[2,3-d]pyrimidin-2(1h)-one
67. 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2s)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1h)-one
Molecular Weight | 560.6 g/mol |
---|---|
Molecular Formula | C30H30F2N6O3 |
XLogP3 | 4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 5 |
Exact Mass | 560.23474516 g/mol |
Monoisotopic Mass | 560.23474516 g/mol |
Topological Polar Surface Area | 102 Ų |
Heavy Atom Count | 41 |
Formal Charge | 0 |
Complexity | 1030 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Sotorasib is indicated in the treatment of adults with KRAS G12C mutant non small cell lung cancer.
Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.
Sotorasib is indicated in the treatment of adults with KRAS G12C mutant non small cell lung cancer. It has a moderate duration of action as it is given daily. Patients should be counselled regarding the risks of hepatotoxicity, interstitial lung disease and pneumonitis; and to avoid breastfeeding during treatment and up to 1 week after the last dose.
Immune Checkpoint Inhibitors
Drugs that block negative regulator IMMUNE CHECKPOINT proteins (e.g., PD-1 RECEPTOR and CTLA-4 ANTIGEN) thereby increasing suppressed immune activation in immunotherapies. (See all compounds classified as Immune Checkpoint Inhibitors.)
L01XX73
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01X - Other antineoplastic agents
L01XX - Other antineoplastic agents
L01XX73 - Sotorasib
Absorption
A 960 mg once daily dose of sotorasib reaches a Cmax of 7.50 g/mL, with a median Tmax of 2.0 hours, and an AUC0-24h of 65.3 h\*g/mL.
Route of Elimination
Sotorasib is 74% eliminated in the feces and 6% eliminated in the urine. 53% of the dose recovered in the feces and 1% of the dose recovered in the urine is in the form of the unchanged parent compound.
Volume of Distribution
The volume of distribution of sotorasib is 211 L.
Clearance
Sotorasib has an apparent clearance at steady state of 26.2 L/h.
Sotorasib is predominantly metabolized through conjugation or by CYP3As.
Sotorasib has a terminal elimination half life of 5.5 1.8 hours.
Normally GTP binds to KRAS, activating the protein and promoting effectors to the MAP kinase pathway. GTP is hydrolyzed to GDP, and KRAS is inactivated. KRAS G12C mutations impair hydrolysis of GTP, leaving it in the active form. Sotorasib binds to the cysteine residue in KRAS G12C mutations, holding the protein in its inactive form. The cysteine residue that sotorasib targets is not present in the wild type KRAS, which prevents off-target effects. This mutation is present in 13% of non small cell lung cancer, 3% of colorectal and appendix cancer, and 1-3% of solid tumors.
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
Severity: Warning
Message: include(../assets/text/seoInfo/137278711.txt): Failed to open stream: No such file or directory
Filename: include/seoInfo.php
Line Number: 77
Backtrace:
File: /var/www/html/application/views/include/seoInfo.php
Line: 77
Function: _error_handler
File: /var/www/html/application/views/include/seoInfo.php
Line: 77
Function: include
File: /var/www/html/application/views/include/product/indexNew.php
Line: 1266
Function: include
File: /var/www/html/application/views/commonNew.php
Line: 442
Function: include
File: /var/www/html/application/controllers/Search.php
Line: 1720
Function: view
File: /var/www/html/index.php
Line: 224
Function: require_once
Severity: Warning
Message: include(): Failed opening '../assets/text/seoInfo/137278711.txt' for inclusion (include_path='.:/usr/share/pear:/usr/share/php')
Filename: include/seoInfo.php
Line Number: 77
Backtrace:
File: /var/www/html/application/views/include/seoInfo.php
Line: 77
Function: _error_handler
File: /var/www/html/application/views/include/seoInfo.php
Line: 77
Function: include
File: /var/www/html/application/views/include/product/indexNew.php
Line: 1266
Function: include
File: /var/www/html/application/views/commonNew.php
Line: 442
Function: include
File: /var/www/html/application/controllers/Search.php
Line: 1720
Function: view
File: /var/www/html/index.php
Line: 224
Function: require_once
A Sotorasib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sotorasib, including repackagers and relabelers. The FDA regulates Sotorasib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sotorasib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sotorasib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Sotorasib supplier is an individual or a company that provides Sotorasib active pharmaceutical ingredient (API) or Sotorasib finished formulations upon request. The Sotorasib suppliers may include Sotorasib API manufacturers, exporters, distributors and traders.
click here to find a list of Sotorasib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sotorasib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Sotorasib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Sotorasib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Sotorasib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sotorasib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Sotorasib suppliers with NDC on PharmaCompass.
Sotorasib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sotorasib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sotorasib GMP manufacturer or Sotorasib GMP API supplier for your needs.
A Sotorasib CoA (Certificate of Analysis) is a formal document that attests to Sotorasib's compliance with Sotorasib specifications and serves as a tool for batch-level quality control.
Sotorasib CoA mostly includes findings from lab analyses of a specific batch. For each Sotorasib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sotorasib may be tested according to a variety of international standards, such as European Pharmacopoeia (Sotorasib EP), Sotorasib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sotorasib USP).
LOOKING FOR A SUPPLIER?